Rheumatoid Arthritis Terminated Phase 4 Trials for Tocilizumab (DB06273)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Terminated4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01661140A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate DosageTreatment
NCT01251120A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid ArthritisTreatment
NCT01283971A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-InhibitorTreatment